Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Kanzler

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Gastroenterology|July 8, 2008
Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damageSteven Dooley, Jafar Hamzavi, Loredana Ciuclan, et al.
Journal of Clinical Gastroenterology|February 28, 2009
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisMarcus Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, et al.
World Journal of Gastroenterology|January 20, 2009
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patientsMarkus Moehler, Martin-F Sprinzl, Murad Abdelfattah, et al.
The American Journal of Gastroenterology|October 16, 2008
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?Elke M Hennes, Ye H Oo, Christoph Schramm, et al.
Oncology Reports|February 22, 2008
PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategyThomas C Wehler, Kirsten Frerichs, Claudine Graf, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 16, 2005
Budesonide in previously untreated autoimmune hepatitisJohannes Wiegand, Andreas Schüler, Stephan Kanzler, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 28, 2022
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II TrialVisvakanth Sivanathan, Christoph Utz, Thomas Thomaidis, et al.
Advances in Therapy|April 14, 2022
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI TrialMichael Dreher, Christian Grohè, Niels-Ulrik Hartmann, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trialArndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Gastroenterology|July 8, 2008
Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damageSteven Dooley, Jafar Hamzavi, Loredana Ciuclan, et al.
Journal of Clinical Gastroenterology|February 28, 2009
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisMarcus Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, et al.
World Journal of Gastroenterology|January 20, 2009
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patientsMarkus Moehler, Martin-F Sprinzl, Murad Abdelfattah, et al.
The American Journal of Gastroenterology|October 16, 2008
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?Elke M Hennes, Ye H Oo, Christoph Schramm, et al.
Oncology Reports|February 22, 2008
PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategyThomas C Wehler, Kirsten Frerichs, Claudine Graf, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 16, 2005
Budesonide in previously untreated autoimmune hepatitisJohannes Wiegand, Andreas Schüler, Stephan Kanzler, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 28, 2022
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II TrialVisvakanth Sivanathan, Christoph Utz, Thomas Thomaidis, et al.
Advances in Therapy|April 14, 2022
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI TrialMichael Dreher, Christian Grohè, Niels-Ulrik Hartmann, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trialArndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
Pageof 5